title: Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone.
authors.affiliation: Division of General Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA. mbloch@aol.com
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Bloch
authors.forename: Jan
authors.initials: J
authors.lastname: Basile